切换至 "中华医学电子期刊资源库"
高级检索
中华老年骨科与康复电子杂志

中华老年骨科与康复电子杂志 ›› 2022, Vol. 08 ›› Issue (01) : 44 -53. doi: 10.3877/cma.j.issn.2096-0263.2022.01.008

Meta分析

富血小板血浆与透明质酸治疗膝关节骨关节炎的meta分析
孙红1, 苏蒙召2, 胥泽玺2, 彭国璇3, 邓进3, 宁旭1, 杨华1,†()   
  1. 1. 550004　贵阳，贵州医科大学附属医院骨科
    2. 550004　贵阳，贵州医科大学临床医学院
    3. 550004　贵阳，贵州医科大学附属医院急诊医学科
  • 收稿日期:2019-12-25 出版日期:2022-02-05
  • 通信作者: 杨华
  • 基金资助:
    国家自然科学基金(NO. 81772403；NO. 81660317); 贵州省科技厅基础研究计划(黔科合基础-ZK[2021]一般391)

Platelet-rich plasma versus hyaluronic acid for the treatment of knee osteoarthritis: A meta-analysis

Hong Sun1, Mengzhao Su2, Zexi Xu2, Guoxuan Peng3, Jin Deng3, Xu Ning1, Hua Yang1,†()   

  1. 1. Department of Orthopaedics, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
    2. Department of Clinical Medical college, Guizhou Medical University, Guiyang 550004, China
    3. Department of Emergence Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
  • Received:2019-12-25 Published:2022-02-05
  • Corresponding author: Hua Yang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孙红, 苏蒙召, 胥泽玺, 彭国璇, 邓进, 宁旭, 杨华. 富血小板血浆与透明质酸治疗膝关节骨关节炎的meta分析[J]. 中华老年骨科与康复电子杂志, 2022, 08(01): 44-53.

Hong Sun, Mengzhao Su, Zexi Xu, Guoxuan Peng, Jin Deng, Xu Ning, Hua Yang. Platelet-rich plasma versus hyaluronic acid for the treatment of knee osteoarthritis: A meta-analysis[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2022, 08(01): 44-53.

目的

本研究旨在探讨富血小板血浆（PRP）与透明质酸（HA）在治疗膝关节骨关节炎（KOA）的疗效差异。

方法

系统检索在线数据库，包括PubMed、Embase、Ovid、Cochrane Library，收集探讨PRP与HA治疗KOA的随机对照研究（RCTs）。主要评价指标为西安大略与麦克马斯特大学骨关节炎指数（WOMAC）疼痛和功能评分。次要评价指标为WOMAC总评分、WOMAC僵硬度评分、国际膝关节文献委员会膝关节评估表（IKDC）评分、疼痛视觉模拟（VAS）评分、EuroQol（EQ）-VAS评分、国际膝关节文献委员会膝关节评估表（KOOS）评分、Lequesne指数和不良事件。采用Review Manager 5.3软件进行数据分析。

结果

本研究纳入19篇随机对照研究，共包含1 818膝。研究结果表明，PRP组患者WOMAC疼痛评分和VAS评分6个月和12个月随访时较HA组患者降低。PRP组患者EQ-VAS评分12个月随访时低于接受HA组患者。此外，1个月、3个月、6个月和12个月随访时，PRP组患者WOMAC功能评分高于HA组患者。两组WOMAC总评分在6个月和12个月随访时差异明显。3个月和6个月随访时，PRP组患者IKDC评分优于HA组患者。两组之间的Lequesne指数、KOOS评分和不良事件发生率差异无统计学意义。

结论

对于膝关节骨关节炎治疗而言，PRP在早期功能康复方面似乎比HA更有效，而在远期疼痛缓解和功能康复方面前者明显优于后者。此外，与HA注射相比，PRP注射不会增加不良事件发生的风险。

关键词: 骨关节炎，膝, 注射，关节内, 富血小板血浆, 透明质酸, meta分析
Objective

This study aimed to evaluate the clinical efficacy of platelet-rich plasma (PRP) injection compared with hyaluronic acid (HA) injection for the treatment of patients diagnosed with knee osteoarthritis (KOA).

Methods

Online databases including PubMed, Embase, Ovid and, Cochrane Library, CNKI and Wanfang database were systematically searched to collect the random controlled trials (RCT) comparing the clinical efficacy between PRP and HA in the treatment of KOA. The primary outcomes were Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function score. Secondary outcomes were WOMAC total score, WOMAC stiffness score, International Knee Documentation Committee (IKDC) score, visual analog scale (VAS) score, EuroQol (EQ)-VAS score, Knee and Osteoarthritis Outcome System (KOOS) score, Lequesne Index score and adverse events. The pooled results were calculated by Review Manager 5.3.

Results

A total of 19 RCTs were enrolled in present study. The pooled results demonstrated that PRP injection was more effective than HA injection in pain relief at 6-month and 12-month of follow-up evaluated by WOMAC pain score and VAS score. EQ-VAS score in the patients treated with PRP injection was lower than that in patients with HA injection at 12-month. Moreover, the patients with PRP injection had a better function recovery than those with HA injection at 1 month, 3-month, 6-month and 12-month after surgery, as evaluated by WOMAC function score. WOMAC total score showed significant difference at 6-months and 12-month after surgery. The IKDC score indicated PRP injection was significantly more effective than HA injection at 3-month and 6-month after surgery. However, the Lequesne Index score, KOOS score and adverse events didn't show any significant difference between the groups.

Conclusions

Intra-articular PRP injection appeared to be more efficacy than HA injection for the treatment of KOA in terms of short-term functional recovery. Moreover, PRP injection was superior to HA injection in terms of long-term pain relief and function improvement. In addition, PRP injection didn't increase the risk of adverse events compared to HA injection.

Key words: Osteoarthritis, knee, Injection, intra-articular, Platelet-rich plasma, Hyaluronic acid, Meta-analysis
图1 文献检索、筛选流程图
表1 纳入文献基本特征
文献 患者数 年龄（岁） 性别（男/女） 体重指数 随访时间（月） 评价体系
  PRP组 HA组 PRP组 HA组 PRP组 HA组 PRP组 HA组    
Cerza等[6] 60 60 66.5 66.2 25/35 28/32 NR NR 1，3，6 WOMAC（total）
Duymus等[7] 33 34 60.4 60.3 1/32 1/33 27.6 28.4 1，3，6，12 VAS，WOMAC
Filardo等[9] 94 89 53.3 57.6 60/34 52/37 26.6 26.9 2，6，12 IKDC，KOOS，EuroQol-VAS
Görmeli等[21] 39（PRP/T） 39 53.7 53.5 16/23 17/22 28.7 29.7 6 IKDC，EuroQol-VAS
  44（PRP/S）   53.8   19/25   28.4      
Paterson等[23] 11 10 49.9 52.7 8/3 7/3 27.9 30.9 3 KOOS，VAS，KQoL-26
Raeissadat等[24] 77 62 56.9 61.1 8/69 15/47 28.2 27 1，12 WOMAC，SF-36
Sanchez等[14] 89 87 60.5 58.9 43/46 42/45 27.9 28.2 1，2，6 WOMAC，LIS
Vaquerizo等[25] 48 48 62.4 64.8 16/32 22/26 30.7 31 6，12 WOMAC，LIS
Montañez-Heredia等[22] 27 26 66.3 61.5 12/15 9/17 29 30.4 3，6 KOOS，VAS，EuroQol-VAS
Cole等[10] 49 50 55.9 56.8 28/21 20/30 27.4 29 3，6，12 WOMAC，VAS，IKDC
Ahmad等[19] 45 44 56.2 56.8 14/31 14/30 26.7 26.5 3，6 IKDC，VAS，US
Yu等[17] 104 88 46.2 51.5 50/54 48/40 NR NR 12 WOMAC
Louis等[18] 24 24 53.2 48.5 14/10 11/13 25.6 27 1，3，6 VAS，WOMAC
Buendia-Lopez等[20] 33 32 56.2 56.6 16/17 15/17 24.9 24.9 6，12 VAS，WOMAC
X-ray，MRI
Li等[26] 15 15 57.6 58.2 6/9 7/8 24.3 24 3，4，6 IKDC，WOMAC，LIS
Su等[13] 25 30 54.2 53.1 11/14 12/18 28.2 28.7 1，3，6，12，18 VAS，WOMAC
  27（PRP/O）   50.7   10/17   28.2      
Lin等[15] # 31 29 61.2 62.5 9/22 10/19 24 26.3 1，2，6，12 IKDC，WOMAC
Huang等[16] 40 40 54.5 54.8 25/15 19/21 25.2 24.5 3，6，9，12 VAS，WOMAC
Di等[8] 85 82 52.7 57.5 53/32 47/35 27.2 26.8 2，12，24，60 IKDC，EuroQol-VAS
表2 PRP和HA给药时间和剂量
文献 PRP HA
注射量 次数 间隔 PRP种类 注射量 次数 间隔
Cerza等[6] 5.5 ml 4 1周 LP-PRP 20 mg/2 ml 4 1周
Duymus等[7] 5 ml 2 1月 LR-PRP 40 mg/2 ml 1 1月
Filardo等[9] 5 ml 3 1周 LR-PRP 30 mg/2 ml 3 1周
Gormeli等[21] 5 ml 3 1周 LR-PRP 30 mg/2 ml 3 1周
Paterson等[23] 3 ml 3 1周 LR-PRP 3 ml 3 1周
Raeissadat等[24] 4~6 ml 2 1月 LR-PRP 20 mg/2 ml 3 1周
Sanchez等[14] 8 ml 3 1周 LP-PRP NR 3 1周
Vaquerizo等[25] 8 ml 3 2周 LP-PRP NR 1 NR
Montañez-Heredia等[22] NR 3 2周 LP-PRP NR 3 2周
Cole等[10] 4 ml 3 1周 LP-PRP 16 mg/2 ml 3 1周
Ahmad等[19] 4 ml 3 2周 LR-PRP 20 mg/2 ml 3 2周
Yu等[17] 2~14 ml 4 1周 LR-PRP 0.1~0.3 mg 4 1周
Louis等[18] 3 ml 1 NR LP-PRP 60 mg/3 ml 1 NR
Buendia-Lopez等[20] 5 ml NR NR LP-PRP 60 mg/2 ml NR NR
Li等[26] 3.5 ml 3 3周 LR-PRP 2 ml 3 3周
Su等[13] 6 ml 2 2周 LR-PRP 2 ml 5 1周
Lin等[15] 5 ml 3 1周 LP-PRP 20 mg/2 ml 3 1周
Huang等[16] 2 ml 3 1周 LP-PRP 4 ml 3 1周
Di等[8] 5 ml 3 1周 LR-PRP 30 mg/2 ml 3 1周
图2 纳入文献质量评价
表3 IKDC、Lequesne Index、VAS、EQ-VAS、KOOS评分meta分析结果
随访时间 评估量表 文献数量 膝关节例数（PRP/HA） 标准差 95% CI P值 I2
1个月 VAS 3 69/74 0.36 -0.38，0.10 No 80%
2个月 EQ-VAS 2 179/171 0.61 -2.10，3.31 No 0%
  IKDC 3 210/200 -1.35 -6.06，3.35 No 58%
3个月 VAS 5 138/142 0.06 -0.54 0.67 No 79%
  IKDC 2 60/59 5.16 0.23，10.10 <0.05 0%
  KOOS symptom 2 105/99 -0.02 -0.54，0.50 No 40%
  KOOS pain 2 105/99 -0.02 -0.29，0.26 No 0%
  KOOS ADL 2 105/99 -0.11 -0.39，0.16 No 0%
  KOOS sport 2 105/99 0.03 -0.24，0.31 No 0%
6个月 VAS 4 136/140 -0.28 -0.98，0.42 No 90%
  EQ-VAS 3 218/210 4.35 -2.30，11.01 No 89%
  IKDC 5 224/216 8.20 1.81，14.58 <0.05 85%
  Lequesne Index 3 152/150 -0.57 -1.59，0.45 No 37%
12个月 VAS 4 131/136 -0.70 -1.03，-0.37 <0.05 63%
  EQ-VAS 2 179/171 3.08 0.34，5.82 <0.05 0%
表4 术后12个月WOMAC疼痛、僵硬、功能和VAS评分亚组分析结果
影响因素 WOMAC疼痛评分 WOMAC功能评分
文献 MD（95% CI） P I2，% 文献 MD（95% CI） P I2，%
总效应 7 -1.55（-2.26，-0.85） <0.0001 87 6 -8.41（-12.39，-4.44） <0.0001 92
PRP注射次数                
1 1 -1.20（-1.76，-0.64） <0.0001 NA 1 -5.90（-8.60，-3.20） <0.0001 NA
≥2 6 -1.67（-2.54，-0.79） <0.0001 89 5 -9.01（-14.06，-3.96） 0.0005 94
PRP离心次数                
单次 4 -1.60（-2.78，-0.43） 0.007 90 3 -8.99（-14.80，-3.19） 0.002 87
两次 3 -1.58（-2.69，-0.47） 0.005 85 3 -7.90（-13.68，-2.12） 0.007 94
PRP类型                
LP PRP 3 -1.62（-2.84，-0.40） 0.009 93 2 -9.07（-15.90，-2.24） 0.009 83
LR PRP 4 -1.55（-2.52，-0.59） 0.002 79 4 -8.15（-13.68，-2.62） 0.004 94
新鲜或冰冻PRP                
新鲜PRP   -1.55（-2.26，-0.85） <0.0001 87 6 -8.41（-12.39，-4.44） <0.0001 92
冰冻PRP   NA NA NA 0 NA NA NA
激活剂使用与否                
是 3 -1.74（-3.02，-0.46） 0.008 88 3 -6.71（-10.99，-2.43） 0.002 87
否 4 -1.49（-2.56，-0.42） 0.006 88 3 -9.91（-16.42，-3.41） 0.003 91
影响因素 WOMAC僵硬评分 VAS评分
文献 MD（95% CI） P I2，% 文献 MD（95% CI） P I2，%
总效应 6 -0.89（-1.25，-0.54） <0.0001 71 4 -0.70（-1.03，-0.37） <0.0001 63
PRP注射次数                
1 1 -0.70（-1.13，-0.27） 0.002 NA 1 -1.30（-1.88，-0.72） <0.0001 NA
≥2 5 -0.95（-1.39，-0.52） <0.0001 77 3 -0.58（-0.82，-0.35） <0.0001 30
PRP离心次数                
单次 3 -1.02（-1.57，-0.47） 0.0003 72 2 -0.52（-1.11，0.06） 0.08 65
两次 3 -0.80（-1.33，-0.26） 0.004 78 2 -0.89（-1.57，-0.22） 0.01 81
PRP类型                
LP PRP 2 -1.21（-2.29，-0.13） 0.03 85 2 -0.75（-1.82，0.33） 0.18 86
LR PRP 4 -0.78（-1.16，-0.41） <0.0001 68 2 -0.63（-0.78，-0.47） <0.0001 0
新鲜或冰冻PRP                
新鲜PRP 6 -0.89（-1.25，-0.54） <0.0001 71 4 -0.70（-1.03，-0.37） 63
冰冻PRP 0 NA NA NA 0 NA NA NA
激活剂使用与否                
是 3 -0.89（-1.56，-0.23） 0.008 83 2 -0.89（-1.57，-0.22） 0.01 81
否 3 -0.93（-1.32，-0.53） <0.0001 54 2 -0.52（-1.11，0.06） 0.08 65
图3 不良事件的森林图
图4 不良事件的漏斗图
表5 不良事件亚组分析
亚组 文献数量 RR（95% CI） P值 I2，%
PRP注射次数        
  1 1 0.50（0.05，5.15） 0.56 NA
  ≥2 10 1.05（0.83，1.32） 0.71 0
PRP离心次数        
  单次 4 0.94（0.70，1.25） 0.65 0
  两次 7 1.28（0.87，1.87） 0.21 6
PRP类型        
  LP PRP 5 1.15（0.80，1.66） 0.46 0
  LR PRP 6 0.95（0.70，1.28） 0.71 0
新鲜或冰冻PRP        
  新鲜PRP 7 1.02（0.80，1.30） 0.88 0
  冰冻PRP 4 1.15（0.54，2.47） 0.72 9
激活剂使用与否        
  是 7 1.05（0.73，1.51） 0.78 0
  否 4 1.02（0.75，1.38） 0.91 35
1
Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis[J]. Nat Rev Rheumatol, 2011, 7(1): 33.
2
Harvey WF, Hunter DJ. The role of analgesics and intra-articular injections in disease management [J]. Med Clin North Am, 2009, 93(1): 201-211.
3
Wehling P, Evans C, Wehling J, et al. Effectiveness of intra-articular therapies in osteoarthritis:A literature review [J]. Ther Adv Musculoskelet Dis, 2017, 9(8): 183-196.
4
Altman R, Hackel J, Niazi F, et al. Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis:A systematic review [J]. Semin Arthritis Rheum, 2018, 48(2): 168-175.
5
Southworth TM, Naveen NB, Tauro TM, et al. The use of Platelet-Rich plasma in symptomatic knee osteoarthritis [J]. J Knee Surg, 2019, 32(1): 37-45.
6
Cerza F, Carni S, Carcangiu A, et al. Comparison between hyaluronic acid and Platelet-Rich plasma, intra-articular infiltration in the treatment of gonarthrosis [J]. Am J Sports Med, 2012, 40(12): 2822-2827.
7
Duymus TM, Mutlu S, Dernek B, et al. Choice of intra-articular injection in treatment of knee osteoarthritis: Platelet-rich plasma, hyaluronic acid or ozone options [J]. Knee Surg Sports Traumatol Arthrosc, 2017, 25(2): 485-492.
8
Di Martino A, Di Matteo B, Papio T, et al. Platelet-Rich plasma versus hyaluronic acid injections for the treatment of knee osteoarthritis: Results at 5 years of a double-blind, randomized controlled trial [J]. Am J Sports Med, 2019, 47(2): 347-354.
9
Filardo G, Di Matteo B, Di Martino AA, et al. Platelet-Rich plasma intra-articular knee injections show no superiority versus viscosupplementation: A randomized controlled trial [J]. Am J Sports Med, 2015, 43(7): 1575-1582.
10
Cole BJ, Karas V, Hussey K, et al. Hyaluronic acid versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis [J]. Am J Sports Med, 2017, 45(2): 339-346.
11
Shen LX, Yuan T, Chen SB, et al. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials [J]. J Orthop Surg Res, 2017, 12(1): 16.
12
Di Y, Han C, Zhao L, et al. Is local platelet-rich plasma injection clinically superior to hyaluronic acid for treatment of knee osteoarthritis? A systematic review of randomized controlled trials [J]. Arthritis Res Ther, 2018, 20(1): 128.
13
Su K, Bai Y, Wang J, et al. Comparison of hyaluronic acid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis [J]. Clin Rheumatol, 2018, 37(5): 1341-1350.
14
Sanchez M, Fiz N, Azofra J, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis [J]. Arthroscopy, 2012, 28(8): 1070-1078.
15
Lin KY, Yang CC, Hsu CJ, et al. Intra-articular injection of platelet-rich plasma is superior to hyaluronic acid or saline solution in the treatment of mild to moderate knee osteoarthritis: A randomized, double-blind, triple-parallel, placebo-controlled clinical trial [J]. Arthroscopy, 2019, 35(1): 106-117.
16
Huang Y, Liu X, Xu X, et al. Intra-articular injections of platelet-rich plasma,hyaluronic acid or corticosteroids for knee osteoarthritis:A prospective randomized controlled study [J]. Orthopade, 2019, 48(3): 239-247.
17
Yu W, Xu P, Huang G, et al. Clinical therapy of hyaluronic acid combined with platelet-rich plasma for the treatment of knee osteoarthritis [J]. Exp Ther Med, 2018, 16(3): 2119-2125.
18
Louis ML, Magalon J, Jouve E, et al. Growth factors levels determine efficacy of platelets rich plasma injection in knee osteoarthritis: A randomized double blind noninferiority trial compared with viscosupplementation [J]. Arthroscopy, 2018, 34(5): 1530-1540.
19
Ahmad HS, Farrag SE, Okasha AE, et al. Clinical outcomes are associated with changes in ultrasonographic structural appearance after platelet-rich plasma treatment for knee osteoarthritis [J]. Int J Rheum Dis, 2018, 21(5): 960-966.
20
Buendía-López D, Medina-Quirós M, Fernández-Villacañas Marín MÁ. Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial [J]. J Orthop Traumatol, 2018, 19(1): 3.
21
Görmeli G, Görmeli CA, Ataoglu B, et al. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: A randomized, double-blind, placebo-controlled trial [J]. Knee Surg Sports Traumatol Arthrosc, 2017, 25(3): 958-965.
22
Montañez-Heredia E, Irízar S, Huertas PJ, et al. Intra-articular injections of platelet-rich plasma versus hyaluronic acid in the treatment of osteoarthritic knee pain: A randomized clinical trial in the context of the Spanish National health care system [J]. Int J Mol Sci, 2016, 17(7): 1064.
23
Paterson KL, Nicholls M, Bennell KL, et al. Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: A double-blind, randomized controlled pilot study [J]. BMC Musculoskelet Disord, 2016, 17(1): 67.
24
Raeissadat SA, Rayegani SM, Hassanabadi H, et al. Knee osteoarthritis injection choices: platelet-rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial) [J]. Clin Med Insights Arthritis Musculoskelet Disord, 2015, 8: 1-8.
25
Vaquerizo V, Plasencia MÁ, Arribas I, et al. Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: A randomized controlled trial [J]. Arthroscopy, 2013, 29(10): 1635-1643.
26
Li M, Zhang C, Ai Z, et al. Therapeutic effectiveness of intra-knee-articular injection of platelet-rich plasma on knee articular cartilage degeneration [J]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2011, 25(10): 1192-1196.
27
Liou JJ, Rothrauff BB, Alexander PG, et al. Effect of platelet-rich plasma on chondrogenic differentiation of adipose-and bone marrow-derived mesenchymal stem cells [J]. Tissue Eng Part A, 2018, 24(20): 1432-1443.
28
Kennedy MI, Whitney K, Evans T, et al. Platelet-rich plasma and cartilage repair [J]. Curr Rev Musculoskelet Med, 2018, 11(4): 573-582.
29
Taniguchi Y, Yoshioka T, Kanamori A, et al. Intra-articular platelet-rich plasma (PRP) injections for treating knee pain associated with osteoarthritis of the knee in the Japanese population: a phase I and IIa clinical trial [J]. Nagoya J Med Sci, 2018, 80(1): 39-51.
30
Meheux CJ, Mcculloch PC, Lintner DM, et al. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review [J]. Arthroscopy, 2016, 32(3): 495-505.
31
31.Gaumet M, Badoud I, Ammann P. Effect of hyaluronic acid-based viscosupplementation on cartilage material properties [J]. Osteoarthritis Cartilage, 2018, 26: S136.
32
Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee:A systematic review [J]. BMC Musculoskelet Disord, 2015, 16(1): 321.
33
Bowman EN, Hallock JD, Throckmorton TW, et al. Hyaluronic acid injections for osteoarthritis of the knee: Predictors of successful treatment [J]. Int Orthop, 2018, 42(4): 733-740.
34
Laudy AB, Bakker EW, Rekers M, et al. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis [J]. Br J Sports Med, 2015, 49(10): 657-672.
35
Han Y, Huang H, Pan J, et al. Meta-analysis comparing platelet-rich plasma vs hyaluronic acid injection in patients with knee osteoarthritis [J]. Pain Medicine, 2019, 20(7): 1418-1429.
36
Zhang H-F, Wang C-G, Li H, et al. Intra-articular platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis [J]. Drug Des Devel Ther, 2018, 12:445-53.
37
Chang KV, Hung CY, Aliwarga F, et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis [J]. Arch Phys Med Rehabil, 2014, 95(3): 562-575.
38
Sundman EA, Cole BJ, Karas V, et al. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis [J]. Am J Sports Med, 2014, 42(1): 35-41.
39
Sakata R, Reddi AH. Platelet-Rich plasma modulates actions on articular cartilage lubrication and regeneration [J]. Tissue Eng Part B Rev, 2016, 22(5): 408-419.
40
Magalon J, Bausset O, Serratrice NA, et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model [J]. Arthroscopy, 2014, 30(5): 629-638.
[1] 欧阳剑锋, 李炳权, 叶永恒, 胡少宇, 向阳. 关节镜联合富血小板血浆治疗粘连性肩周炎的疗效[J]. 中华关节外科杂志(电子版), 2023, 17(06): 765-772.
[2] 许正文, 李振, 侯振扬, 苏长征, 朱彪. 富血小板血浆联合植骨治疗早期非创伤性股骨头坏死[J]. 中华关节外科杂志(电子版), 2023, 17(06): 773-779.
[3] 张思平, 刘伟, 马鹏程. 全膝关节置换术后下肢轻度内翻对线对疗效的影响[J]. 中华关节外科杂志(电子版), 2023, 17(06): 808-817.
[4] 罗旺林, 杨传军, 许国星, 俞建国, 孙伟东, 颜文娟, 冯志. 开放性楔形胫骨高位截骨术不同植入材料的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(06): 818-826.
[5] 闫文, 谢兴文, 顾玉彪, 雷宁波, 马成, 于文霞, 高亚雄, 张磊. 微小RNA与全膝关节置换术后深静脉血栓的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 842-846.
[6] 夏传龙, 迟健, 丛强, 连杰, 崔峻, 陈彦玲. 富血小板血浆联合关节镜治疗半月板损伤的临床疗效[J]. 中华关节外科杂志(电子版), 2023, 17(06): 877-881.
[7] 李善武, 叶永杰, 王兵, 王子呓, 银毅, 孙官军, 张大刚. 胫骨高位截骨与单髁置换的早期疗效比较[J]. 中华关节外科杂志(电子版), 2023, 17(06): 882-888.
[8] 张中斌, 付琨朋, 朱凯, 张玉, 李华. 胫骨高位截骨术与富血小板血浆治疗膝骨关节炎的疗效[J]. 中华关节外科杂志(电子版), 2023, 17(05): 633-641.
[9] 马鹏程, 刘伟, 张思平. 股骨髋臼撞击综合征关节镜手术中闭合关节囊的疗效影响[J]. 中华关节外科杂志(电子版), 2023, 17(05): 653-662.
[10] 韩李念, 王君. 放射性皮肤损伤治疗的研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 533-537.
[11] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[12] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[13] 武慧铭, 郭仁凯, 李辉宇. 机器人辅助下经自然腔道取标本手术治疗结直肠癌安全性和有效性的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(05): 395-400.
[14] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[15] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号